Southeast Asia’s healthcare and tech or (healthtech) sector pulses with life again after two challenging years. The first half of 2025 witnessed startups from the region raising US$108 million spanning across 16 deals.
What makes this recovery notable is its selective nature. Rather than chasing every telemedicine or wellness app, investors are placing bigger bets on startups that can deliver defensible technology, regulatory approval and clear regional scalability.
We look at the rise of digital healthcare marketplaces in Southeast Asia’s tier-2 cities
Singapore leads the comeback
Singapore continues to trailblaze the sector. With its robust regulatory frameworks, strong governmental support, as well as a dense ecosystem of researchers, clinicians and investors, the country’s startup landscape accounted for the lion’s share of investment for the sector, primarily anchored by Nuevocor’s US$45 million Series B round to further advance gene therapy for inherited cardiac arrest back in Q2 2025.
These developments signal Singapore’s readiness as a burgeoning hub for high-barrier healthtech plays, specifically in diagnostics, advanced therapeutics and AI-driven platforms requiring clinical validation.
However, the country’s small domestic ecosystem means that scaling abroad is imperative. For many of its startups, regional expansion remains both an opportunity and a challenge at the same time.
Designing solutions that meet regulatory compliance requirements for the ASEAN markets, localising payment and insurance models for underbanked populations and establishing cross-border partnerships with key players of the industry could potentially help convert Singapore’s innovation edge to withstand headwinds and strengthen market leadership across Southeast Asia.
Indonesia emerges as a burgeoning market
Across the ocean, Indonesia is witnessing significant investor attention as the country continues to chart its own pathway, thanks to its need for affordable and accessible healthcare.
In May 2025, the country sought to enhance cooperation with Sweden as a means to adopt its healthtech system. The country’s geographical location and uneven health infrastructure (2.1 nurses per 1000 population and 0.6 doctors per 1000 population) signal the scale of unmet demand.
For investors, this gap highlights new opportunities to provide healthtech solutions to bridge this divide through digital platforms, remote care or hybrid delivery models. By bypassing traditional clinic-heavy models, startups in Indonesia can deliver remote consultations and pharmaceutical access directly to their population.
These tools enable appointment scheduling, test result access ,and at-home communication with healthcare providers will further strengthen this model, improving patient outcomes whilst simultaneously creating scalable solutions with clear cost-efficiency gains that can be emulated across underserved markets in the region.
AI-driven diagnostics and remote care attract capital
The Covid-19 pandemic played a key role in catalysing digital care, but what’s powering investor interest now is artificial intelligence. Across the globe, digital health venture capital remains resilient, with funding reaching US$6.4 billion during the first half of 2025, an increase from US$6 billion in H1 2024 according to reports.
Much of this momentum is being driven by AI: healthcare AI companies alone attracted nearly US $4 billion in funding in H1 2025, accounting for more than half of overall digital health investments, Fierce Healthcare reports.
For Southeast Asia, this spotlights a strong alignment between global investor priorities and the region’s most pressing healthcare gaps. In markets where doctor-to-patient ratios remain low and healthcare access is uneven, AI-driven solutions provide a scalable way to triage patients, deliver routine care remotely and reduce pressure on overstretched health systems.
With global capital continuing to flow into AI healthtech, Southeast Asian startups that can localise these models for fragmented but fast-digitising markets stand to capture outsized investor interest.
Healthtech meets fintech
In Southeast Asia, where insurance penetration remains low and out-of-pocket healthcare spending remains at an all-time high, the convergence of healthtech and fintech is becoming a compelling lever for accessibility.
Startups like MiCare, which streamlines the process of medical claims through its digital e-claims platform and HealthMetrics, which provides employers with simplified healthcare and insurance management tools, showcase how embedded finance can be integrated directly into the healthcare ecosystem.
This trend is further reinforced by the region’s rapidly growing insurtech landscape. Industry players like Singapore’s igloo’s expansion to Indonesia, Vietnam and the Philippines through B2B2C insurance models.
For investors, this signals a critical frontier: embedding financial tools into healthcare not only improves affordability and uptake but also creates scalable, dual-revenue models that can be replicated across Southeast Asia’s diverse markets.
Global players bet on SEA scalability
Global Investors and healthcare corporations have also returned to the scene with a strong focus on creating scalable solutions across a multitude of emerging markets that share similar healthcare access gaps.
For global funds, defensibility is a crucial element as investors actively seek out startups that demonstrate robust intellectual property, clinical validation, as well as compliance accommodating to the ever-evolving regulatory frameworks. Startups can no longer rely on a “one size fits all” approach.
For example, a telemedicine model from Vietnam needs to show that it can adapt to Indonesia’s payment system or Thailand’s regulatory environment needs to be attractive for cross-border investors.
This shift signals that the next wave of capital will not simply reward first-movers, but those who can build resilient, compliant and scalable businesses capable of weathering scrutiny in multiple jurisdictions.
Where does the industry go next?
Southeast Asia’s healthtech rebound in H1 2025 signals not a return to the boom years, but the start of a more measured and mature investment cycle. Singapore remains the anchor hub, Indonesia the growth frontier and AI-driven diagnostics the sector’s rising star.
Whether this momentum holds depends on two factors: if early-stage funding picks up to keep the innovation pipeline alive and if founders can prove that their models scale across the region’s fragmented healthcare systems.
For now, the industry looks less like it’s chasing the hype and more like it’s building the foundations for sustainable growth. Healthtech in Southeast Asia may finally be moving from experiment to execution